---
title: "Reviva Pharmaceuticals (RVPH.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RVPH.US/norm.md"
symbol: "RVPH.US"
name: "Reviva Pharmaceuticals"
parent: "https://longbridge.com/en/quote/RVPH.US.md"
datetime: "2026-05-20T07:33:21.092Z"
locales:
  - [en](https://longbridge.com/en/quote/RVPH.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RVPH.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RVPH.US/norm.md)
---

# Reviva Pharmaceuticals (RVPH.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -0.4600 | -0.5670 | -1.10 | -2.43 | -2.64 |
| ROE | -98.01% | -204.14% | -784.39% | 984.49% | 1410.92% |
| Revenue | - | - | - | - | - |
| Net income | -3.20M | -3.37M | -4.01M | -6.05M | -6.43M |
| Operating income | -3.27M | -3.56M | -4.03M | -6.07M | -6.54M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 23.56M | 15.92M | 14.33M | 11.63M | 7.08M |
| Leverage | 1.35 | 1.84 | 3.15 | -25.34 | -1.59 |
| BVPS | 1.36 | 1.47 | 0.9445 | -0.1350 | -1.91 |
| Turnover | - | - | - | - | - |
| Cash & STI | 22.19M | 14.44M | 13.18M | 10.36M | 5.29M |
| Inv & Rec | - | - | - | - | - |
| LT assets | - | - | - | - | - |
| Net debt | -21.96M | -14.03M | -13.18M | -10.25M | -5.07M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -3.80M | -5.80M | -5.59M | -5.01M | -8.19M |
| Investing CF | - | - | - | - | - |
| Financing CF | 11.55M | 7.05M | 8.41M | 10.09M | 7271.00 |
| Free CF | -3.73M | -4.97M | -4.16M | -2.20M | -5.79M |
| OCF coverage | -2164.73% | - | -4935.70% | -4513.79% | -3503.98% |
| Repaid & issued | - | 406875.00 | - | - | - |
| CapEx | - | - | - | - | - |